In human cells and precision-cut lung tissue, vapour damaged the deep lung’s barrier within a day and blunted the antiviral response to a subsequent infection.

Most of what is known about vaping and the lungs concerns the airways. A study in JCI Insight from National Jewish Health looks further in, at the distal lung — the alveoli and the capillaries wrapped around them, where gas exchange actually happens and where damage is least reversible.

The finding is that brief exposure to e-cigarette vapour injures that region quickly, that the stress response outlasts the exposure, and that a lung exposed beforehand handles a subsequent virus worse.

The senior author is Irina Petrache, a pulmonologist and chief of the Division of Pulmonary, Critical Care and Sleep Medicine at National Jewish Health.

What was exposed

The work used human material rather than animals: distal lung epithelial and endothelial cells, and precision-cut human lung tissue — thin slices of real lung in which the architecture and the mix of cell types are preserved. These were exposed to e-cigarette vapour alone, and separately to vapour followed by respiratory virus infection.

Precision-cut tissue is a meaningful step up from cultured cells for this question. Barrier function is a property of cells in their proper arrangement, and a slice of lung retains the epithelium sitting against its basement membrane with endothelium nearby, which a monolayer in a dish does not.

Twenty-four hours

Within a day, vapour damaged the distal lung’s protective barrier.

That barrier is what keeps the air space and the bloodstream separate. When it fails, fluid moves into the alveoli and pathogens move the other way, which is the mechanism underlying acute lung injury.

The vapour also triggered cellular stress and impaired the cells’ ability to clear damaged components — a reference to autophagy, the housekeeping process by which a cell digests its own broken parts. A cell under stress that cannot clear the resulting debris accumulates it, which is a plausible route from repeated insult to chronic change.

Cell growth and repair slowed, and cell death increased. Taken together these describe a tissue losing ground on both sides of the ledger: more damage, less capacity to make it good.

“Our findings suggest that even short-term vaping exposure can initiate injury in the deepest and most delicate regions of the lung,” Petrache said.

The part that persisted

The more consequential result is about time. Signs of stress were still present ten days after a five-day exposure ended, with lasting changes in barrier function, tissue remodelling and Th1 immunity — the arm of the immune system that handles viral infection.

A stress response that outlives its cause by twice its own duration is not the same thing as transient irritation. It suggests the tissue has shifted into a different state rather than simply reacting, which is how chronic disease usually begins.

The viral experiments make that concrete. Prior vaping exposure increased SARS-CoV-2 viral burden and suppressed several antiviral genes after infection.

“Importantly, some effects persisted after exposure ended and altered the immune response to a subsequent viral infection,” Petrache said.

This is the finding with the clearest practical reading. It describes a lung that has been made more hospitable to a virus, and it does so through a mechanism — suppressed Th1 responses and antiviral gene expression — rather than by correlation. It also, importantly, concerns a lung whose vaping exposure had already stopped.

What a preclinical study is

The authors note that the findings need confirmation in human studies, and that repeated exposure could potentially contribute to chronic lung disease. Both qualifications are load-bearing.

No person was exposed to anything here. Cells and tissue slices were exposed in a laboratory, and the dose, duration and delivery of vapour to tissue in a chamber are not the dose, duration and delivery a person inhaling from a device receives. Human lung slices come from donated tissue, usually from surgical resections, which means they come from people who needed lung surgery.

The release also reports no quantitative results at all — no magnitude for the barrier disruption, no fold-change in viral burden, no count of samples or donors, no indication of which antiviral genes were suppressed or by how much. For a result whose strength depends on how large these effects were, that is the central omission.

Nor does it state the vapour composition. E-cigarette aerosol varies enormously with device, power setting, liquid formulation and whether nicotine or flavourings are present, and findings attributed to “vaping” in one preparation may not transfer to another. Flavouring compounds in particular have been implicated in several of the cell-level effects reported in this literature.

The disclosure gap

One absence is worth flagging specifically. The release states neither funding sources nor conflicts of interest.

In most fields that is an irritation. In research on tobacco and nicotine products it is more than that, because the field has a long documented history of industry-funded work shaping the evidence base in both directions, and readers have learned to check. The omission here says nothing about who funded this study — National Jewish Health is a respiratory research hospital with no obvious stake — and it is exactly the detail that should not be missing.

What the work adds, read conservatively, is mechanism in human tissue for something the epidemiology cannot yet show. Vaping is too recent for long-term human outcome data to exist, which leaves a gap that preclinical work on real human lung is well placed to fill — and this study fills part of it with a specific and checkable claim: brief exposure, persistent stress, weakened antiviral defence.

The paper was published on 22 September 2026. The release names only the senior author and does not give the full author list.

---

Notes

1. “E-cigarette exposure triggers distal lung cell injury, persistent lung stress response, and antiviral immune suppression.” JCI Insight, 2026. DOI: 10.1172/jci.insight.198757.
2. National Jewish Health. “Even brief e-cigarette use can cause lasting lung damage and weaken defenses against respiratory viruses, study finds.” EurekAlert!, 5 October 2026. https://www.eurekalert.org/news-releases/1146576.

Photo by Dede Avez on Pexels.com